CCDC26基因rs4295627单核苷酸多态性与胶质瘤易感性关系的Meta分析

A Meta analysis of association between CCDC26 rs4295627 single nucleotide polymorphism and glioma susceptibility

目的探讨卷曲螺旋结构域-26（CCDC26）基因rs4295627多态性与胶质瘤易感性的关系。方法计算机检索PubMed、CBM、万方和CNKI数据库收录的CCDC26基因rs4295627多态性与胶质瘤相关的文献．检索时限均为建库至2016年4月1日。依照预先设定的纳入和排除标准筛选有关的病例-对照研究，提取和评价资料质量后，采用Stata12．0软件进行Meta分析。结果共纳入16项病例．对照研究，其中病例组5356例，对照组8874例。Meta分析结果显示，CCDC26基因rs4295627多态性与胶质瘤易感性显著相关（BUSA：比值比（0R）=1.32，95％CI：1．174-1．489，P=-0．000：BAvsAA：OR=1．330，95％CI：1．204～1．470，P=-0．000；BA＋BBvsAA：OR=1．366。95％CI：1．212-1．539．P=-0．001；BBvsAA：OR=1．751，95％CI：1．270～2．413，P=0．001；BBvsBA＋AA：OR=1．592．95％CI：1．181～2．145，P=-0．002）。根据种族类型的亚组分析发现该基因多态性与高加索人种胶质瘤易感性显著相关（BvsA：OR=1．344，95％CI：1．225～1．476，P=-0．000；BAvs5AA：OR=1．338，95％CI：1．244-1．439，P=-0．000；BA＋BBUSAA：0R=1.381，95％CI：1．264～1．508，P=-0．000；BB vsAA：OR=1．906，95％CI：1．370～2．651，P=0．000）。结论CCDC26基因rs4295627多态性与胶质瘤易感性相关，预期可作为胶质瘤诊断、筛查的标记物。

Objective To certify the relationship between coiled-coil domain-containing 26 （CCDC26） rs4295627 polymorphism and glioma susceptibility by a Meta analysis. Methods Several databases as PubMed, CBM, CNKI and Wanfang Databases were searched; all papers were searched from the date of establishment to April 1, 2016. All case-control studies of CCDC26 rs4295627 polymorphism and glioma were collected according to the inclusion and exclusion criteria. The quality of the included trials was assessed and a Meta analysis was performed by State 12.0 software. Results A total of 16 case-control studies involving 5,356 cases and 8,874 controls were enrolled. The results of Meta analyses showed a significant relation between CCDC26 rs4295627 polymorphism and glioma susceptibility （B vs. A： odds ratio [OR]=1.322, 95%CI=1.174-1.489, P=-0.000; BA vs. AA： OR=1.330, 95%CI=1.204-1.470, P=0.000; BA＋BB vs. AA： OR=1.366, 95%CI=1.212-1.539, P=-0.001; BB vs. AA： OR=1.751, 95%CI=1.270-2.413, P=0.001; BB vs. BA＋AA： OR=1.592, 95%CI： 1.181-2.145, P=0.002）. In the stratification analysis by ethnicity, a significant association between CCDC26 rs4295627 polymorphism and glioma susceptibility in Caucasian population was covered （B vs. A： OR=1.344, 95% CI=1.225-1.476, P=0.000; BA vs. AA： OR=1.338, 95%CI： 1.244-1.439, P=0.000; BA＋BB vs. AA：OR=1.381, 95%CI： 1.264-1.508, P=-0.000; BB vs. AA： OR=1.906, 95%CI： 1.370-2.651, P=-0.000）. Conclusion The CCDC26 rs4295627 polymorphism has strong association with glioma susceptibility, which can be considered as a biomarker for the diagnosis and screening ofglioma patients.